NCT04677153View on ClinicalTrials.gov

Rapid HCV Treatment Access for Persons Who Use Drugs

NACompletedINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

August 6, 2021

Primary Completion Date

February 23, 2024

Study Completion Date

September 23, 2024

Conditions
Hepatitis C Virus Infection, Response to Therapy of
Interventions
OTHER

Test and treat plus peer mentors

Rapid start of HCV treatment at OTP within days of HCV diagnosis. Participants will receive 8 weeks of glecaprevir/pibrentasvir and will work with a peer mentor during and after treatment.

OTHER

Usual care

Participants are referred to another location for HCV treatment.

Trial Locations (4)

21287

Johns Hopkins University, Baltimore

35294

University of Alabama, Birmingham

94143

University of California, San Francisco, San Francisco

M5G 2C4

University Health Network Toronto, Toronto

Sponsors

Collaborators (1)

AbbVie
All Listed Sponsors
collaborator

AbbVie

INDUSTRY

lead

Johns Hopkins University

OTHER